Albumin nano-encapsulation of piceatannol enhances its anticancer potential in colon cancer via downregulation of nuclear p65 and HIF-1α

Alaa A.A. Aljabali; Hamid A. Bakshi; Faruk L. Hakkim; Yusuf A. Haggag; Khalid M. Albatanyeh; Mazhar S. Al Zoubi; Bahaa Al-Trad; Mohamed M. Nasef; Saurabh Satija; Meenu Mehta; Kavita Pabreja; Vijay Mishra; Mohammed Khan; Salem Abobaker; Ibrahim M. Azzouz; Harish Dureja; Ritesh M. Pabari; Ashref Ali K. Dardouri; Prashant Kesharwani; Gaurav Gupta; Shakti Dhar Shukla; Parteek Prasher; Nitin B. Charbe; Poonam Negi; Deepak N. Kapoor; Dinesh Kumar Chellappan; Mateus Webba da Silva; Paul Thompson; Kamal Dua; Paul McCarron; Murtaza M. Tambuwala

doi:10.3390/cancers12010113

Albumin nano-encapsulation of piceatannol enhances its anticancer potential in colon cancer via downregulation of nuclear p65 and HIF-1α

Alaa A.A. Aljabali, Hamid A. Bakshi, Faruk L. Hakkim, Yusuf A. Haggag, Khalid M. Albatanyeh, Mazhar S. Al Zoubi, Bahaa Al-Trad, Mohamed M. Nasef, Saurabh Satija, Meenu Mehta, Kavita Pabreja, Vijay Mishra, Mohammed Khan, Salem Abobaker, Ibrahim M. Azzouz, Harish Dureja, Ritesh M. Pabari, Ashref Ali K. Dardouri, Prashant Kesharwani, Gaurav GuptaShakti Dhar Shukla, Parteek Prasher, Nitin B. Charbe, Poonam Negi, Deepak N. Kapoor, Dinesh Kumar Chellappan, Mateus Webba da Silva, Paul Thompson, Kamal Dua, Paul McCarron, Murtaza M. Tambuwala

Research output: Contribution to journal › Article › peer-review

80 Scopus citations

Abstract

Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therpautice potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possiable human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.

Original language	English (US)
Article number	113
Journal	Cancers
Volume	12
Issue number	1
DOIs	https://doi.org/10.3390/cancers12010113
State	Published - Jan 2020
Externally published	Yes

Bibliographical note

Funding Information:
Funding: Financial support for this work was provided by Ulster University in the form of the Research ChallengeFund(RCF-2014)strategicawardtoDrMurtazaM.Tambuwala

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

Albumin nanoparticles
Colon cancer
HIF-1α
Nuclear P65
Piceatannol

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.3390/cancers12010113

Find It

Find It at U of M Libraries

Cite this

Aljabali, A. A. A., Bakshi, H. A., Hakkim, F. L., Haggag, Y. A., Albatanyeh, K. M., Al Zoubi, M. S., Al-Trad, B., Nasef, M. M., Satija, S., Mehta, M., Pabreja, K., Mishra, V., Khan, M., Abobaker, S., Azzouz, I. M., Dureja, H., Pabari, R. M., Dardouri, A. A. K., Kesharwani, P., ... Tambuwala, M. M. (2020). Albumin nano-encapsulation of piceatannol enhances its anticancer potential in colon cancer via downregulation of nuclear p65 and HIF-1α. Cancers, 12(1), Article 113. https://doi.org/10.3390/cancers12010113

Aljabali, AAA, Bakshi, HA, Hakkim, FL, Haggag, YA, Albatanyeh, KM, Al Zoubi, MS, Al-Trad, B, Nasef, MM, Satija, S, Mehta, M, Pabreja, K, Mishra, V, Khan, M, Abobaker, S, Azzouz, IM, Dureja, H, Pabari, RM, Dardouri, AAK, Kesharwani, P, Gupta, G, Shukla, SD, Prasher, P, Charbe, NB, Negi, P, Kapoor, DN, Chellappan, DK, da Silva, MW, Thompson, P, Dua, K, McCarron, P & Tambuwala, MM 2020, 'Albumin nano-encapsulation of piceatannol enhances its anticancer potential in colon cancer via downregulation of nuclear p65 and HIF-1α', Cancers, vol. 12, no. 1, 113. https://doi.org/10.3390/cancers12010113

@article{32afc39faf5e4a8c8a297188a55ecd39,

title = "Albumin nano-encapsulation of piceatannol enhances its anticancer potential in colon cancer via downregulation of nuclear p65 and HIF-1α",

abstract = "Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therpautice potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possiable human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.",

keywords = "Albumin nanoparticles, Colon cancer, HIF-1α, Nuclear P65, Piceatannol",

author = "Aljabali, {Alaa A.A.} and Bakshi, {Hamid A.} and Hakkim, {Faruk L.} and Haggag, {Yusuf A.} and Albatanyeh, {Khalid M.} and {Al Zoubi}, {Mazhar S.} and Bahaa Al-Trad and Nasef, {Mohamed M.} and Saurabh Satija and Meenu Mehta and Kavita Pabreja and Vijay Mishra and Mohammed Khan and Salem Abobaker and Azzouz, {Ibrahim M.} and Harish Dureja and Pabari, {Ritesh M.} and Dardouri, {Ashref Ali K.} and Prashant Kesharwani and Gaurav Gupta and Shukla, {Shakti Dhar} and Parteek Prasher and Charbe, {Nitin B.} and Poonam Negi and Kapoor, {Deepak N.} and Chellappan, {Dinesh Kumar} and {da Silva}, {Mateus Webba} and Paul Thompson and Kamal Dua and Paul McCarron and Tambuwala, {Murtaza M.}",

note = "Funding Information: Funding: Financial support for this work was provided by Ulster University in the form of the Research ChallengeFund(RCF-2014)strategicawardtoDrMurtazaM.Tambuwala Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = jan,

doi = "10.3390/cancers12010113",

language = "English (US)",

volume = "12",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

TY - JOUR

T1 - Albumin nano-encapsulation of piceatannol enhances its anticancer potential in colon cancer via downregulation of nuclear p65 and HIF-1α

AU - Aljabali, Alaa A.A.

AU - Bakshi, Hamid A.

AU - Hakkim, Faruk L.

AU - Haggag, Yusuf A.

AU - Albatanyeh, Khalid M.

AU - Al Zoubi, Mazhar S.

AU - Al-Trad, Bahaa

AU - Nasef, Mohamed M.

AU - Satija, Saurabh

AU - Mehta, Meenu

AU - Pabreja, Kavita

AU - Mishra, Vijay

AU - Khan, Mohammed

AU - Abobaker, Salem

AU - Azzouz, Ibrahim M.

AU - Dureja, Harish

AU - Pabari, Ritesh M.

AU - Dardouri, Ashref Ali K.

AU - Kesharwani, Prashant

AU - Gupta, Gaurav

AU - Shukla, Shakti Dhar

AU - Prasher, Parteek

AU - Charbe, Nitin B.

AU - Negi, Poonam

AU - Kapoor, Deepak N.

AU - Chellappan, Dinesh Kumar

AU - da Silva, Mateus Webba

AU - Thompson, Paul

AU - Dua, Kamal

AU - McCarron, Paul

AU - Tambuwala, Murtaza M.

N1 - Funding Information: Funding: Financial support for this work was provided by Ulster University in the form of the Research ChallengeFund(RCF-2014)strategicawardtoDrMurtazaM.Tambuwala Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2020/1

Y1 - 2020/1

N2 - Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therpautice potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possiable human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.

AB - Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC–BSA nanoparticles (NPs). These PIC–BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1α. Our results indicate that PIC–BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1α in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC–BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC–BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC–BSA NPs, enhances its therpautice potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possiable human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.

KW - Albumin nanoparticles

KW - Colon cancer

KW - HIF-1α

KW - Nuclear P65

KW - Piceatannol

UR - http://www.scopus.com/inward/record.url?scp=85077603084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077603084&partnerID=8YFLogxK

U2 - 10.3390/cancers12010113

DO - 10.3390/cancers12010113

M3 - Article

AN - SCOPUS:85077603084

SN - 2072-6694

VL - 12

JO - Cancers

JF - Cancers

IS - 1

M1 - 113

ER -

Albumin nano-encapsulation of piceatannol enhances its anticancer potential in colon cancer via downregulation of nuclear p65 and HIF-1α

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this